Tuesday, 21 August 2018

WHO HCV Guidelines recommends Ascletis' Ravidasvir

09 August 2018 | News

Ravidasvir is a next-generation, best-in-class and pan-genotypic HCV NS5A inhibitor with a high genetic barrier to resistance

Ascletis Pharma Inc  announced  Ravidasvir is recommended by the World Health Organization (WHO) Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection (July 2018) as a future pan-genotypic direct-acting antivirals agent (DAA).

 

Ascletis received the acceptance letter for Ravidasvir new drug application (NDA) from the China Food and Drug Administration (CFDA) on August 1.

 

Ravidasvir is a next-generation, best-in-class and pan-genotypic HCV NS5A inhibitor with a high genetic barrier to resistance.

 

Globally, Ravidasvir has completed three phase III clinical trials with more than 1000 patients enrolled. Ravidasvir in combination with Ganovo® (RDV/DNV Regimen) is the first all-oral interferon-free HCV regimen developed by a domestic company in China.

 

A phase II/III clinical trial in China has shown that RDV/DNV Regimen demonstrated a cure rate of 99 % (SVR12) with a short treatment duration of 12 weeks in genotype 1 patients. In patients with baseline NS5A resistance mutations, RDV/DNV Regimen demonstrated a cure rate of 100% (SVR12).

 

"We are so excited that Ravidasvir is recommended as a pan-genotypic DAA by the WHO HCV guidelines." Jinzi J. Wu, Ph.D., Ascletis' founder, President and CEO, commented, "Ravidasvir is not only recognized by international academic communities, but also recognized by an internationally renowned public health organization.

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Is provision of cheap drugs having limited effects in the fight against HCV in SE Asia?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls